CARLSBAD, Calif., Oct. 23, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will receive $1.1 million from Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) as its portion of the upfront fees in Alnylam's recently announced collaboration with Genzyme. In addition, Isis has the potential to receive royalty payments and a portion of future milestone payments. Already this year, Isis has earned $2.7 million from Alnylam as a result of Alnylam's licenses that were supported by Isis' patents, further emphasizing the value of Isis' innovation and the leadership role Isis has played in the field of RNA-based technology.
"We have a broad and valuable patent estate built upon our innovations and discoveries related to RNA-based technologies that provides us with extensive protection for our drugs and our technologies. Our business strategy maximizes the value of these innovations by granting partners access to our technology for uses that are outside our key areas of focus. Using this strategy, we have been able to generate more than $400 million from the sale and licensing of our intellectual property," said B. Lynne Parshall, chief operating officer and chief financial officer at Isis.
Isis is the leading company in RNA-based technology and owns or controls more than 1,500 issued patents. As such, Isis holds patents for numerous applications of antisense technology, including RNAi, and for novel targets, such as microRNAs being developed by Regulus, which was co-founded by Isis and Alnylam. In 2004, Isis and Alnylam entered into a strategic relationship in which Alnylam obtained an exclusive license to Isis' intellectual property for double-stranded oligonucleotide therapeutics that mediate RNAi. In return, Isis received an upfront payment and financial participation in future transactions supported by Isis' patents.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV